Literature DB >> 2148699

Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men.

A Rosengren1, L Wilhelmsen, E Eriksson, B Risberg, H Wedel.   

Abstract

OBJECTIVE: To examine the association between the serum lipoprotein (a) concentration and subsequent coronary heart disease.
DESIGN: Prospective case-control study based on a six year follow up of a general population sample of men aged 50 at baseline in 1983-4. Serum samples were frozen at the time of the baseline examination and kept at -70 degrees C for six years, after which the lipoprotein (a) concentrations in the samples were measured in cases and controls.
SETTING: City of Gothenburg, Sweden.
SUBJECTS: 26 Men, from a general population sample of 776 men, who had sustained a myocardial infarction or died of coronary heart disease during the six years and 109 randomly selected controls from the same sample who had remained free of myocardial infarction. In neither cases nor controls was there a history of myocardial infarction at baseline. MAIN OUTCOME MEASURES: Proportion of myocardial infarction or deaths from coronary heart disease, or both, in relation to the serum lipoprotein (a) concentration.
RESULTS: Men who suffered coronary heart disease had significantly higher serum lipoprotein (a) concentrations than controls (mean difference 105 mg/l; 95% confidence interval 18 to 192 mg/l). Men with the highest fifth of serum lipoprotein (a) concentrations (cut off point 365 mg/l) suffered a coronary heart disease rate which was more than twice that of men with the lowest four fifths of concentrations. Logistic regression analysis showed the serum lipoprotein (a) concentration to be significantly associated with coronary heart disease independently of other risk factors.
CONCLUSION: The serum lipoprotein (a) concentration in middle aged men is an independent risk factor for subsequent myocardial infarction or death from coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2148699      PMCID: PMC1664422          DOI: 10.1136/bmj.301.6763.1248

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  25 in total

1.  Lipoprotein Lp(a). A risk factor for myocardial infarction.

Authors:  G Hoefler; F Harnoncourt; E Paschke; W Mirtl; K H Pfeiffer; G M Kostner
Journal:  Arteriosclerosis       Date:  1988 Jul-Aug

2.  Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction.

Authors:  A Murai; T Miyahara; N Fujimoto; M Matsuda; M Kameyama
Journal:  Atherosclerosis       Date:  1986-02       Impact factor: 5.162

3.  Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma.

Authors:  G Utermann; H J Menzel; H G Kraft; H C Duba; H G Kemmler; C Seitz
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

4.  cDNA sequence of human apolipoprotein(a) is homologous to plasminogen.

Authors:  J W McLean; J E Tomlinson; W J Kuang; D L Eaton; E Y Chen; G M Fless; A M Scanu; R M Lawn
Journal:  Nature       Date:  1987 Nov 12-18       Impact factor: 49.962

5.  A study of methods of identification and estimation of Lp(a) lipoprotein and of its significance in health, hyperlipidaemia and atherosclerosis.

Authors:  K W Walton; J Hitchens; H N Magnani; M Khan
Journal:  Atherosclerosis       Date:  1974 Sep-Oct       Impact factor: 5.162

6.  Effects of a lacto-ovo vegetarian diet on serum concentrations of cholesterol, triglyceride, HDL-C, HDL2-C, HDL3-C, apoprotein-B, and Lp(a).

Authors:  J R Masarei; I L Rouse; W J Lynch; K Robertson; R Vandongen; L J Beilin
Journal:  Am J Clin Nutr       Date:  1984-09       Impact factor: 7.045

7.  Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen.

Authors:  D L Eaton; G M Fless; W J Kohr; J W McLean; Q T Xu; C G Miller; R M Lawn; A M Scanu
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

8.  Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

Authors:  A Hamsten; U de Faire; G Walldius; G Dahlén; A Szamosi; C Landou; M Blombäck; B Wiman
Journal:  Lancet       Date:  1987-07-04       Impact factor: 79.321

9.  Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease.

Authors:  P N Durrington; M Ishola; L Hunt; S Arrol; D Bhatnagar
Journal:  Lancet       Date:  1988-05-14       Impact factor: 79.321

10.  Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography.

Authors:  G H Dahlen; J R Guyton; M Attar; J A Farmer; J A Kautz; A M Gotto
Journal:  Circulation       Date:  1986-10       Impact factor: 29.690

View more
  48 in total

Review 1.  Pathogenesis and pathology of coronary heart disease syndromes.

Authors:  P M Ridker; E M Antman
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 2.300

2.  Relationship of lipoprotein(a) levels to physical activity and family history of coronary heart disease.

Authors:  S Martín; R Elosua; M I Covas; M Pavesi; J Vila; J Marrugat
Journal:  Am J Public Health       Date:  1999-03       Impact factor: 9.308

3.  Clinical implications of elevated lipoprotein(a).

Authors:  A von Eckardstein; G Assmann
Journal:  Curr Atheroscler Rep       Date:  2001-07       Impact factor: 5.113

Review 4.  Lipoprotein(a): an elusive cardiovascular risk factor.

Authors:  Lars Berglund; Rajasekhar Ramakrishnan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-02       Impact factor: 8.311

5.  Expressed hypervariable polymorphism of apolipoprotein (a).

Authors:  M I Kamboh; R E Ferrell; B A Kottke
Journal:  Am J Hum Genet       Date:  1991-11       Impact factor: 11.025

Review 6.  Novel markers of inflammation in atherosclerosis.

Authors:  Salim S Virani; Venkateshwar R Polsani; Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2008-04       Impact factor: 5.113

7.  Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease.

Authors:  C Sandholzer; E Boerwinkle; N Saha; M C Tong; G Utermann
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

8.  Serum LP(A) levels in randomized healthy men from different European countries.

Authors:  M Cigolini; J C Seidell; M G Zenti; G Bonadonna; L Zambelli; J P Deslypere; F Contaldo; A Cruz; J Charzewska; G Targher
Journal:  Eur J Epidemiol       Date:  1993-09       Impact factor: 8.082

9.  Association between impaired glucose tolerance and circulating concentration of Lp(a) lipoprotein in relation to coronary heart disease.

Authors:  M Farrer; F L Game; C J Albers; H A Neil; P H Winocour; M F Laker; P C Adams; K G Alberti
Journal:  BMJ       Date:  1993-10-02

10.  The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate.

Authors:  D J Rader; W Cain; K Ikewaki; G Talley; L A Zech; D Usher; H B Brewer
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.